EUCTR2006-006515-76-GB进行中（未招募）不适用
A Dose Targeted Phase I/II Study To Evaluate The Feasibility, Safety, And Biological Effects Of Intravenous Administration of A Wild-Type Reovirus (REOLYSIN®) in Combination With Paclitaxel and Carboplatin To Patients With Advanced Malignancies
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Each patient MUST:
- •1.Phase I: Have histologically proven advanced or loco-regionally advanced cancer, including head/neck cancer, which is not amenable to curative therapy refractory to standard therapy or for which no curative standard therapy exists and for which paclitaxel or carboplatin is appropriate palliative chemotherapy. Previous malignancy or those with 2 malignancies that are active are eligible. The latter are eligible provided it is reasonable to treat both malignancies with a platinum and taxane.
- •Phase II: Patients with advanced or metastatic head/neck cancer that are refractory to standard therapy or for which no curative standard therapy exists.
- •2.Have evidence of measurable or evaluable disease.
- •3.Have NO continuing acute toxic effects (except alopecia) of any prior radiotherapy, chemotherapy, or surgical procedures, i.e., all such effects must have resolved to Common Terminology Criteria for Adverse Events (CTCAE, Version 3.0) Grade =1. Surgery (except biopsies) must have occurred at least 28 Days prior to study enrolment.
- •4.Be at least 18 years of age.
- •5.Have received NO chemotherapy, radiotherapy, immunotherapy and NO hormonotherapy within 28 Days prior to receiving study drug; patients may continue to receive LHRH analogue therapy for prostate cancer if they have rising PSA.
- •6.Have an ECOG Performance Score of =2.
- •7.Have a life expectancy of at least 3 months.
- •8.Have baseline laboratory results as follows:
- •oAbsolute neutrophil count (ANC) = 1.5 x 109 [SI units 109/L]
- •oPlatelets = 100 x109 [SI units 109/L] (without platelet transfusion)
- •oHaemoglobin = 9.0 g/dL [SI units gm/L] (with or without RBC transfusion)
- •oSerum creatinine = 1.5 x upper limit of normal (ULN)
- •oBilirubin = 1.5 x ULN
- •oAST/ALT = 2.5 x ULN
- •oNegative pregnancy test for females of childbearing potential.
- •9.Have signed an informed consent indicating that the patient is aware of the neoplastic nature of their disease and have been informed of the procedures of the protocol, the experimental nature of the therapy, alternatives, potential benefits, side effects, risks, and discomforts.
- •10.Be willing and able to comply with scheduled visits, the treatment plan, and laboratory tests.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •No patient may:
- •1.Receive concurrent therapy with any other investigational anticancer agent while on study (except patients with rising PSA who may continue on LHRH analogue therapy).
- •2.Have known brain metastasis(es). Such a patient must be excluded from this clinical trial because of their poor prognosis and because of frequent development of progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. However, patients who have had treated cerebral metastases that have been stable for 6 months are eligible
- •3.Be on immunosuppressive therapy or have known HIV infection or active hepatitis B or C.
- •4.Be a pregnant or breast-feeding woman. Female patients of childbearing potential must agree to use effective contraception, must be surgically sterile, or must be postmenopausal. Male patients must agree to use effective contraception or be surgically sterile. Barrier methods are a recommended form of contraception.
- •5.Have clinically significant cardiac disease (New York Heart Association, Class III or IV) including pre-existing arrhythmia, uncontrolled angina pectoris, myocardial infarction 1 year prior to study entry, or grade 2 or higher compromised left ventricular ejection fraction.
- •6.Have dementia or altered mental status that would prohibit informed consent.
- •7.Have any other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Principal Investigator, would make the patient inappropriate for this study.
研究者
相似试验
进行中（未招募）
1 期
A study to investigate the optimum dose, the efficacy and the safety of sifalimumab in adult patients with Systemic Lupus Erythematosus, a disease of the immune systemMedDRA version: 14.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2010-024069-30-GBAstraZeneca AB400
已完成
2 期
A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults with Systemic Lupus ErythematosusNL-OMON35833Astra Zeneca12
进行中（未招募）
不适用
A study to investigate the optimum dose, the efficacy and the safety of sifalimumab in adult patients with Systemic Lupus Erythematosus, a disease of the immune systemSystemic Lupus ErythematosusEUCTR2010-024069-30-BGAstraZeneca AB400
进行中（未招募）
不适用
A study to investigate the optimum dose, the efficacy and the safety of sifalimumab in adult patients with Systemic Lupus Erythematosus, a disease of the immune systemMedDRA version: 13.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2010-024069-30-ESAstraZeneca AB544
进行中（未招募）
不适用
A study to investigate the optimum dose, the efficacy and the safety of sifalimumab in adult patients with Systemic Lupus Erythematosus, a disease of the immune systemSystemic Lupus ErythematosusEUCTR2010-024069-30-HUAstraZeneca AB400